A line-up of presentations from CRISPR Therapeutics AG (NASDAQ: CRSP) fueled the stock rally by 22% last week alone, with the stock ending last week at a new yearly high. Value investors will ask if the stock will pull back or continue its positive momentum.
Fundamentally, CRISPR is in a promising area of science of gene editing. Both novel and life-changing, the company’s updated method for searching and replacing genes has bulls excited. Dubbed MAGESTIC for "multiplexed accurate genome editing with short, trackable, integrated cellular barcodes," cell survival improved by seven times.
If used commercially, the MAGISTIC system always needs a certain CRISPR enzyme. Thus those using the system will need to pay licensing fees to the patent holder.
This is a breakthrough in screening and editing genes and is still built on the CRISPR-Cas9 platform as the paper explains.
Related: Intellia Therapeutics, Inc. (NASDAQ: NTLA), Editas Medicine (NASDAQ: EDIT), and Sangamo Therapeutics, Inc. (NASDAQ: SGMO)
Tandem Diabetes Care (NASDAQ: TNDM) is the second stock in the medical instruments and supplies market to notice. The stock zoomed from $8 to $12 (by May 18) in May. On April 30, the company announced a CE certification for t:slim X2 Insulin Pump with Dexcom (NASDAQ: DXCM).
Tandem has a market cap of around $650 million. The company raised $100 million on Apr 26 and has enough cash to run through to the end of 2019.
